With an incidence of 1.5 cases per million people, thymic epithelial tumors (TETs) account for about 20% of overall mediastinal tumors and 47% of anterior mediastinal tumors[@b1][@b2][@b3]. As pathologically classified by The World Health Organization (WHO) in 2004, TETs are now classified as either one of 5 types of thymomas (types A, AB, B1, B2, and B3) or thymic carcinoma[@b4]. It is shown that the WHO classification could reflect both oncologic behavior and prognostic feature of TETs well[@b3][@b5][@b6][@b7]. Usually type A and AB thymomas are grouped as low risk thymomas with low invasiveness and better prognosis, while type B1, B2 and B3 as high-risk thymomas which are more aggressive[@b5]. Studies have shown that there are different optimal therapeutic strategies for different stages of TETs[@b8][@b9][@b10][@b11][@b12]. For example, in high-risk thymomas and thymic carcinoma patients, adjuvant chemo-radiotherapy is necessary after surgery. Also, at the time of surgery, neo-adjuvant chemo/radio therapy is demonstrated to contribute to a complete resection[@b10][@b11]. Thus an accurate pre-operative identification of the histologic subtype and staging are highly necessary to guide the optimal intervention for TETs patients. However, up to date this objective has not been adequately achieved.

Imaging is very important for the noninvasively preoperative staging and oncological follow up[@b13]. Computed Tomography (CT) scan is used in the evaluation of majority of TETs cases, which can provide detailed information regarding tumor size, shape, homogeneity and so forth. However, current CT scan cannot effectively differentiate different WHO pathological classifications[@b14]. Although several studies have suggested that CT manifestation parameters (tumor size, shape, necrosis or cystic change, capsule integrity, invasion to the adjacent tissue, lymphadenopathy, the presence of pleural effusion, etc) demonstrated significant differences in different TETs types[@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21], up to date these parameters could not effectively predict WHO classifications with satisfactory sensitivity and specificity. Besides, the sample sizes of these studies are relatively small, which limits their ability to provide a precise answer for our research question of interest. In a previous pilot study, we proposed a new parameter of risk of aggressiveness graded by CT, and evaluated its predictive role in 66 TETs patients[@b22]. In this study, we conducted a comprehensive retrospective analysis of 216 TETs cases to better characterize the prediction value of this parameter for TETs classifications. Additionally, we evaluated, for the first time, two other new variables of grade of contrast enhancement and multiple nodules with fibrous septum to determine their efficacy in preoperatively differentiating low versus high risk TETs.

Results
=======

General data
------------

### Main clinical presentation

A total of 216 patients (130 males and 86 females) with a mean age of 50.0 ± 12.6 were enrolled in this study ([Supplementary Table 2](#s1){ref-type="supplementary-material"}). Tumors of the majority of participants (199; 92.1%) were completely resected, and the pathology results of the remaining 17 (7.9%) patients were obtained by core biopsy. According to the histological and immunohistochemical results, from WHO pathological classification perspective there were 11 (5.1%) patients of type A, 47 (21.8%) of type AB, 38 (17.6%) of type B1, 43 (19.9%) of type B2, 21 (9.7%) of type B3, and 56 (25.9%) of thymic carcinoma ([Supplementary Table 2](#s1){ref-type="supplementary-material"}).

There was no significant difference in age among different pathological types of thymic tumors (P \> 0.05), but type B3 thymoma and thymic carcinoma appeared more in males (P = 0.013) ([Table 1](#t1){ref-type="table"}). Among these patients, 51 (23.6%) had no symptoms, especially in patients of types A and AB thymoma (6.55% and 16.34% respectively); 79 (36.5%) were diagnosed with myasthenia gravis (MG), while MG rarely existed in patients of thymic carcinoma (2%); 37 (17.1%) had symptoms of chest tightness and chest pain; and 35 (16.2%) had respiratory symptoms including cough, expectoration, short breath, dyspnea, et al ([Table 1](#t1){ref-type="table"}).

Distribution of CT Features among patients with different WHO pathological classifications
------------------------------------------------------------------------------------------

The distribution of CT features among different WHO classifications were demonstrated in [Table 2](#t2){ref-type="table"}. Overall, tumor size, boundary, necrosis or cystic change, capsule integrity, homogeneity, the presence of septum, invasion to the adjacent tissue, the presence of pericardiac or pleural effusion, and lymphadenopathy were significantly different among different pathological types of TETs (all P \< 0.001). Multiple nodules with fibrous septum appeared in 77% of type AB thymomas and were rare in other subtypes. There were no significant differences in shape and calcification between the different pathological types of TETs (P = 0.206 and 0.474, respectively) ([Table 2](#t2){ref-type="table"}). It seemed that lymphogenous spread was not a common occurrence in TETs. Lymph node involvement was seen in 3 (1.9%) thymoma patients and in 21 (37.5%) thymic carcinoma patients.

Contrast-enhanced CT features among patients with different WHO pathological classifications
--------------------------------------------------------------------------------------------

As shown in [Table 3](#t3){ref-type="table"}, The CE~max~ of types A, AB, B1, B2, and B3 thymic tumors and thymic carcinoma were significantly different. Overall there was significant difference for CE~max~ between low risk (types A, AB) and high risk (B1, B2, B3 and thymic carcinoma) subtypes (P \< 0.001) ([Figure 1](#f1){ref-type="fig"}). The patterns of contrast enhancement were also significantly different among different pathological types of TETs (P \< 0.001) ([Table 3](#t3){ref-type="table"}).

[Figure 2](#f2){ref-type="fig"} demonstrated the receiver operating characteristic (ROC) curve for the diagnostic performance of the maximal contrast-enhanced range (CE~max~) in identifying the low from high risk TETs. The area under the curve (AUC) was 0.80 (95% CI, 0.71 to 0.89). And the best cutoff point for CE~max~ is at 25.5 HU, when the sensitivity and specificity for identifying low risk subtypes being 78.8% and 68.5%, respectively ([Figure 2](#f2){ref-type="fig"}).

Relationship between the CT grade of aggressive risk and WHO pathological classifications
-----------------------------------------------------------------------------------------

As shown in [Table 2](#t2){ref-type="table"}, for the grade of aggressive risk parameter, 63 (29.2%) patients were categorized in Grade I, 57 (26.4%) in Grade II, 21 (9.7%) in Grade III, and 75 (34.7%) in Grade IV ([Table 2](#t2){ref-type="table"}). The relationship between different grades of aggressive risk and WHO pathological subtypes was demonstrated in [Figure 3](#f3){ref-type="fig"}. There was a strong correlation between CT grade of aggressive risk and WHO pathological subtypes (r = 0.801, P \< 0.001). Also this parameter could potentially suggest low versus high risk subtypes effectively (Grade I suggested a higher possibility of being low risk subtype, Grade III and IV suggested a higher possibility of being high risk subtype), which might provide additional evidence for subtype prediction. Representative CT images for different grades of aggressive risk were shown in [Supplementary Figure 1A--H](#s1){ref-type="supplementary-material"}.

Discussion
==========

The noninvasively preoperative prediction of WHO histologic subtypes is important for guiding treatment strategies for TET patients. Type A and AB thymomas generally behave as a benign tumor and type B1 is a low-grade malignant tumor with the 10-year survival rate being over 90%. Type A, AB, and B1 thymomas usually have more chances of complete resection than other subtypes[@b23]. Type B2 has a greater degree of malignancy, and type B3 shows a poor prognosis, like thymic carcinoma and malignant tumors of other organs[@b5]. Patients with type B2 or B3 thymomas, or thymic carcinoma might require adjuvant chemo-radiotherapy[@b23].

In this study, we employed the largest cohort of TETs patients up to date to investigate whether CT diagnostic parameters could identify staging of this cancer. The conventional CT findings can determine tumor size, shape, density, involvement of the capsule and surrounding tissues, all of which are related to the WHO histologic classification and clinical stages of TETs. In our study, a greater average tumor diameter indicates a higher probability that the tumor is malignant. It is very often for thymic carcinoma to have a maximum diameter of larger than 8 cm (49.1%). Low risk thymic tumors (types A, AB) are often round or oval with a clear, smooth margin, complete capsule and homogenous density; on the contrary, high risk subtypes (types B1, B2, B3 and thymic carcinoma) are often irregular in shape or deep lobulated. There is usually a higher rate of invasion by direct extending to adjacent structures including pericardium, large vessels or lung. The lobulation rate is between 60% and 89% based on previous study[@b23]. Focusing on common CT manifestation parameters, we detected that size, boundary, capsule, homogeneity, septa, necrotic or cystic change, pleural effusion, lymphadenopathy, and invasion of adjacent tissues demonstrated significant differences among the 6 TETs subtypes, which confirms previous findings[@b14][@b15][@b16][@b17][@b18]. However, there was no significant difference for tumor shape among the different pathological types of TETs (P = 0.206), which is inconsistent with previous studies[@b14][@b15][@b16][@b17][@b18]. The finding that there was no significant difference for calcification among the different pathological types of TETs (P = 0.474) confirms the conclusion from a previous systematic review[@b24].

CT enhancement is very often used in TETs diagnosis since it can better reveal the tumor shape and invasion to adjacent tissues, as well as demonstrate the blood supply to tumor tissues. For the first time, we demonstrated that significantly different degrees of CT enhancement exist for different TETs WHO classifications. The area under the ROC curve for differentiating low (types A, AB) from high risk subtypes (types B1 B2, B3 and thymic carcinoma) reaches 80%. And the best cutting point for CE~max~ is at 25.5 HU, when the sensitivity and specificity of determining low risk subtypes are 78.8% and 68.5%, respectively. Generally speaking, degree of CT enhancement may represent levels of blood supply, thus should increase with more advanced tumor stages. Research has indicated a significant correlation between tumor angiogenesis and invasiveness in patients with TETs[@b25]. However, our finding is out of expectation in suggesting that low risk subtype of thymoma (type A and AB) demonstrated a high degree of CT enhancement while high risk ones demonstrated a much lower degree of CT enhancement. Pan et al studied the clinicopathologic characteristics of spindle cell thymoma (medullary, WHO type A) and mixed spindle/lymphocytic thymoma (WHO type AB), and found that the short-spindled pattern of type A thymoma may commonly arrange in a hemangiopericytic or microcystic pattern[@b26], which may explain why a higher degree of CT enhancement exist in low risk subtypes in our study. To the best of our knowledge, this exploration of degree of CT enhancement and stage of TETs has never been investigated before, and focusing on our clinical question itself, this interesting finding implies that degree of CT enhancement can probably predict the classifications of TETs.

The Masaoka staging system has been widely used in the clinical management of TETs with the clinical stage remaining the most important prognostic factor of thymoma[@b5][@b27]. A recent study demonstrated a close relationship between preoperative CT thymoma staging and postoperative Masaoka clinical staging[@b28]. Based on CT demonstrations of pathological classifications and Masaoka stages of primary mediastinal tumor, we proposed a parameter of aggressive risk. In this comprehensive analysis of 216 TETs patients, we detected a strong correlation between CT grade of aggressive risk and WHO histological classification (r = 0.801, P \< 0.001). Our data also suggested that such a parameter could potentially help differentiate low from high risk TET subtypes, which could potentially add confidence in such a determination besides the parameter of degree of CT enhancement.

Interestingly, in our study we detected that multiple nodule with fibrous septum appeared in over 77% of type AB thymomas, but was rare in other subtypes and if existed, with a different manifestation. Histologically, type AB thymoma showed multiple nodules separated by fibrous bands[@b4]. The multiple nodules with fibrous septum features on CT imaging are consistent with the macroscopic appearance of a type AB thymoma ([Supplementary Fig 2A](#s1){ref-type="supplementary-material"})[@b26]. However, high risk TET subtypes especially thymic carcinoma appear as mainly deep lobulation or spiculate protuberance without tumor septum ([Supplementary Fig 2B](#s1){ref-type="supplementary-material"}). This finding is useful in determining type AB thymomas. The detection of tumor septum can potentially be useful as a marker for type AB thymoma.

Our study also has limitations to acknowledge. Firstly, we did not analyze CT characteristics of thymic carcinoma according to their specific pathological classifications. Certain subtypes of thymic carcinoma such as neuroendocrine carcinomas have differentiated CT manifestations and prognosis, which warrants further study. Secondly, the complete survival data of these patients are not available, which intimidates the possibility to determine the relationship between survival and variables of risk of aggressiveness and degree of CT enhancement. The fact that survival rates of TETs patients, especially for those in low risk subgroups, are relatively high and a very long follow up will be required to collect these data. Further study for elucidating this research question is warranted. Thirdly, the hemodynamic analysis of TETs based on histopathology was not conducted, and further study for resolving this research question will be needed to clarify the mechanism of CT enhancement finding in this study.

In conclusion, using the largest sample up to date, we identified that several variables which are largely unreported before, including degree of CT enhancement, risk of aggressiveness, and multiple nodule with fibrous septum could preoperatively help determine the WHO pathological classification of TETs patients, especially for the low risk and high risk subtypes. A combined prediction using these variables will provide a better guidance for appropriate therapeutic strategies for TETs patients.

Methods
=======

Participants
------------

Between February 2009 and March 2014, 216 patients of TETs were sequentially enrolled in Tangdu Hospital, whose diseases were further confirmed by surgical pathology or needle biopsy. Plain CT scan was performed on all 216 patients, among which contrast-enhanced CT scan was further performed on 141 patients. All plain and enhanced CT data were available, combined with histological and immuno-histochemical examinations for WHO pathological classification. Demographic data and clinical symptoms were also collected. This study was conducted in accordance with the declaration of Helsinki. This study was approved by Ethics Committee of Tangdu Hospital of the Fourth Military Medical University, and informed consent was waived.

Image Acquisition and Analysis
------------------------------

Philips 256-slice CT (Brilliance iCT, Philips Healthcare, Cleveland, USA), GE 64-slice CT (GE-Medical-Systems, Milwaukee, USA) and Siemens 16-slice CT (Somatom Sensation, Siemens, Erlangen, Germany) were used. In all patients, the scan range for plain CT was from the thoracic inlet to the diaphragmatic level. The slice thickness and interval were each 5 mm. Other scanning parameters were 120 kV and 200 mAs. Before the CT scanning, patients were instructed to hold their breath to avoid motion artifacts. Dual-phase arterial and venous enhanced CT was performed in a proportion of patients after obtaining their agreement. A total of 40 to 120 mL (1.5 mL/kg weight) of contrast medium (Ultravist, Schering Pharmaceutical Ltd, Guangzhou, 300 mg/mL) were injected by using a power injector at a rate of 3.0 mL/s. Scanning parameters were same as plain CT. All imaging data underwent further multi-planar reconstruction and were analyzed at medical imaging workstation.

Two senior radiologists reviewed the imaging data, according to the recommendation of the Nomenclature Committee of the Fleischner Society[@b29]. They were told before the review that the patients had thymic epithelial tumors, but they were blinded to the specific pathological classifications. Decisions regarding the CT findings were reached by consensus. All monitors showed images obtained using both mediastinal (width, 320 Hounsfield Units (HU); level, 35 HU) and lung (width, 1000 HU; level, −600 HU) window settings.

CT imaging features of TETs were assessed for the following parameters: 1) Shape and boundary: the tumor shape was evaluated based on the ratio of the long axis diameter to the short axis diameter. It was classified as round if the long- to short-axis ratio was less than or equal to 1.5, oval if the ratio was greater than 1.5 but less than 2.0, or irregular if the ratio was greater than or equal to 2.0. Marginal characteristics were subclassified as smooth, lobulated, or irregular; 2) Size: the longest diameter of the tumor was measured where the tumor appeared largest on an axial image. Based on this, tumors were divided into three groups: ≤4.0 cm, 4.0 \~ 8.0 cm, and ≥8.0 cm. The mean diameter (D~mean~) was calculated by D~mean~ = (a + b + c)/3, and the maximal cross-section was used to measure the long and short diameters; 3) Homogeneity: with a standard mediastinal window setting, areas with a CT value difference less than 10 HU represented homogeneity, otherwise represented heterogeneity. The presences of calcification, necrosis or cystic change were also evaluated; 4) Capsule integrity: almost complete (smooth or shadow lobulation), partial complete (deep lobulation or spiculate protuberance); 5) Involvement of adjacent tissues: mediastinal fat layer of peritumour (clear, blurred, or disappeared), pleura and pericardium (irregular interface with an absent space between tumor and pleura or pericardium; thickening; effusion); Mediastinal blood vessels (absent space between tumor and blood vessels; oppression, deformation and occlusion of vessels; tumor thrombus in the vessels; tumor capsuling \>1/4 circumference of vessel); 6) Lymph node enlargement: A measurement of the shortest lymph node diameter \>1.0 cm was defined as lymph node enlargement; 7) Pattern of contrast enhancement: a maximal difference of CT values between plain scan and contrast-enhancement phase in the solid component of tumor, which is denoted as maximal contrast-enhanced range (CE~max~). This parameter was divided into three groups of mild, moderate and strong contrast enhancement, with indication of CE~max~ ≤ 20.0 HU, 20.0--40.0 HU, and ≥40.0 HU, respectively; Region of interests (ROIs) should not be near superior vena cava which is strong contrast enhancement evident, and should not be areas of fringe, calcification or necrotic. The ROIs should be uniform, thus the sizes should be relatively homogeneous. To avoid quantum noise, ROIs should be no less than 50 pixels, and be like round shape. Depending on actual situation, size of ROIs can be small if lesion is relatively small; when lesion is relatively large, several ROIs with the same size can be selected and the average number is calculated; 8) Risk of aggressiveness: This 4-grade system of aggressive risk is based on CT findings of TETs subtypes and Masaoka stages of primary mediastinal tumors[@b3][@b30] ([Supplementary Table 1](#s1){ref-type="supplementary-material"}).

Statistical analysis
--------------------

Numerical variables were denoted as mean and standard deviation. The between-group comparisons of gender, age, and CT manifestations (including tumor size, shape, boundary, homogeneity, calcification, necrosis or cystic change, capsular integrity, tumor septum, invasion to the adjacent tissue, the presence of pericardiac or pleural effusion, and lymphadenopathy) were conducted using the chi-square test or Fisher\'s exact test. The between-group comparisons of D~mean~ and CE~max~values were conducted using ANOVA test. Spearman correlation analyses were conducted to determine the correlation between the grade of aggressive risk and WHO pathology subtypes of TETs. ROC analyses were performed to determine optimum thresholds for differentiating the low risk and the high risk TETs by CE~max~ value and to calculate the sensitivity, specificity, and area under curve (AUC) for identifying low risk thymoma. P \< 0.05 indicated a statistically significant difference. SPSS17.0 software (SPSS Inc, Chicago, IL, USA) was used for statistical analyses.
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###### Clinical and Demographic Characteristics of the Patients

                           A (n = 11)   AB (n = 47)   B1 (n = 38)   B2 (n = 43)   B3 (n = 21)   Thymic carcinoma (n = 56)                     
  ----------------------- ------------ ------------- ------------- ------------- ------------- --------------------------- -------------------------------------
  **Sex**                                                                                                                                  0.013
  Males                      6(55)        25(53)        17(45)        23(53)        16(76)               43(77)                               
  Females                    5(45)        22(47)        21(55)        20(47)         5(24)               13(23)                               
  Age                                                                                                                                      0.466
  \<45 years                 2(18)        17(36)        15(40)        20(46)         5(24)               17(30)                               
  45--55 years               2(18)        13(28)        10(26)        12(28)         5(24)               14(25)                               
  \>55 years                 7(64)        17(36)        13(34)        11(26)        11(52)               25(45)                               
  **Myasthenia gravis**                                                                                                                   \<0.001
  Yes                        5(45)        21(45)        22(58)        27(63)         3(14)                1(2)                                
  No                         6(55)        26(55)        16(42)        16(37)        16(76)               55(98)                               
  **Symptoms**                                                                                                              \<0.001[\*](#t1-fn1){ref-type="fn"}
  No symptom                 6(55)        16(34)         9(23)         9(21)         2(10)                9(16)                               
  Myasthenia                 5(45)        21(45)        22(58)        27(63)         3(14)                1(2)                                
  Chest pain                  ---          1(2)          3(8)          1(2)          7(33)               25(45)                               
  Respiratory symptoms        ---          7(15)         3(8)          5(12)         7(33)               13(23)                               
  Others                      ---          2(4)          1(3)          1(2)          2(10)                8(14)                               

\*P-values were calculated by Monte Carlo Test.

###### Relationship between CT findings and WHO histologic subtypes

  Variable                                        A (n = 11)    AB (n = 47)   B1(n = 38)    B2(n = 43)    B3(n = 21)    Thymic Carcinoma (n = 56)                P-value
  ---------------------------------------------- ------------- ------------- ------------- ------------- ------------- --------------------------- -----------------------------------
  **Size**                                                                                                                                                           
  Maximum diameter - no.(%)                                                                                                                                       0.000
  \<4                                                4(36)        15(32)        20(53)        24(56)         8(38)               11(20)                              
  4--8                                               6(55)        18(38)        15(40)        15(35)         8(38)               19(34)                              
  \>8                                                1(9)         14(30)         3(8)          4(9)          5(24)               26(46)                              
  Mean diameter(mean ± sd; cm)                    3.97 ± 2.37   5.52 ± 2.47   4.36 ± 1.78   3.95 ± 1.73   5.27 ± 2.68          6.00 ± 2.31          0.000[\*](#t2-fn1){ref-type="fn"}
  **Shape- no.(%)**                                                                                                                                               0.206
  Round                                              6(55)        20(42)        14(37)        16(37)         9(43)               22(39)                              
  Oval                                               5(45)        23(49)        16(42)        18(42)         5(24)               18(32)                              
  Irregular                                           ---          4(9)          8(21)         9(21)         7(33)               16(29)                              
  **Boundary- no.(%)**                                                                                                                                            0.000
  Smooth                                             8(73)        12(25)         9(24)          ---           ---                  ---                               
  Lobulated                                          3(27)        30(64)        19(50)        29(67)         4(19)                8(14)                              
  Irregular                                           ---          5(11)        10(26)        14(33)        17(81)               48(86)                              
  **Capsule integrity - no.(%)**                                                                                                                                  0.000
  Almost complete                                   11(100)       31(66)        13(34)         8(19)          ---                 1(2)                               
  Partial                                             ---         16(34)        25(66)        35(81)        21(100)              55(98)                              
  **Homogeneity- no.(%)**                                                                                                                                         0.002
  Homogeneous                                        9(82)        24(51)        15(40)        23(53)         7(33)               14(25)                              
  Heterogeneous                                      2(18)        23(49)        23(61)        20(47)        14(67)               42(75)                              
  **Septum - no.(%)**                                                                                                                                             0.000
  Yes                                                2(18)        36(77)         5(13)         2(5)          1(5)                  ---                               
  No                                                 9(82)        11(23)        33(87)        41(95)        20(95)               56(100)                             
  **Calcification - no.(%)**                                                                                                                                      0.474
  Yes                                                1(9)         12(26)        13(34)        11(26)         8(38)               19(34)                              
  No                                                10(91)        35(74)        25(66)        32(74)        13(62)               37(66)                              
  **Necrotic or cystic change - no.(%)**                                                                                                                          0.000
  Yes                                                1(9)         14(30)        16(42)        15(35)        10(48)               39(70)                              
  No                                                10(91)        33(70)        22(58)        28(65)        11(52)               17(30)                              
  **Pericardiac or Pleural effusion - no.(%)**                                                                                                                    0.000
  Yes                                                 ---          1(2)          4(11)        12(28)        12(57)               49(88)                              
  No                                                11(100)       46(98)        34(89)        31(72)         9(43)                7(12)                              
  **Lymphadenopathy - no.(%)**                                                                                                                      0.000[†](#t2-fn2){ref-type="fn"}
  Yes                                                 ---           ---           ---          2(5)          1(5)                21(37)                              
  No                                                11(100)       47(100)       38(100)       41(95)        20(95)               35(63)                              
  **Involvement of adjacent tissues - no.(%)**                                                                                                                    0.000
  Yes                                                 ---           ---          6(16)        15(35)        19(90)               55(98)                              
  No                                                11(100)       47(100)       32(84)        28(65)         2(10)                1(2)                               
  **Grade of aggressive risk by CT - no.(%)**                                                                                                                        
  Grade I                                           11(100)       31(66)        13(34)         8(19)          ---                  ---                               
  Grade II                                            ---         15(32)        19(50)        20(46)         2(10)                1(2)                               
  Grade III                                           ---          1(2)          2(5)          4(9)          7(33)                7(12)                              
  Grade IV                                            ---           ---          4(11)        11(26)        12(57)               48(86)                              

\*P-values were calculated by ANOVA;

^†^P-values were calculated by Monte Carlo Test.

###### Relationship between patterns of contrast-enhancement and WHO histologic subtypes

  Variable                    A (n = 7)       AB (n = 26)     B1 (n = 22)     B2 (n = 24)     B3 (n = 15)    Thymic Carcinoma (n = 47)                P-value
  ------------------------ ---------------- --------------- --------------- --------------- --------------- --------------------------- -----------------------------------
  CE~max~                                                                                                                                                 
  Mean ± sd(HU)             41.1 ± 15.8^a^   33.0 ± 9.6^b^   23.0 ± 8.7^c^   22.0 ± 8.2^c^   20.9 ± 9.5^c^         23.6 ± 9.1^c^         0.000[\*](#t3-fn1){ref-type="fn"}
  Pattern of CE - no.(%)                                                                                                                 0.000[†](#t3-fn2){ref-type="fn"}
  Mild                           ---             2(8)          10(45.5)         14(58)           8(53)                16(34)                              
  Moderate                      3(43)           15(57)         10(45.5)          9(38)           6(40)                29(62)                              
  Strong                        4(57)            9(35)           2(9)            1(4)            1(7)                  2(4)                               

\*P-values were calculated by one-way ANOVA; the different alphabet represented a significant difference between the two groups;

^†^P-values were calculated by Monte Carlo Test.

CE~max~: maximal contrast-enhanced range; CE: contrast enhancement.

[^1]: These authors contributed equally to this article.
